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Summary. Conventional light microscopy, immunocyto- 
chemistry, electron microscopy and in situ hybridization 
were used to evaluate the effect of dopamine agonists 
(bromocriptine-LAR and bromocriptine) on the mor- 
phology of surgically removed prolactin (PRL)-produc- 
ing pituitary adenomas. Dopamine agonist therapy re- 
sulted in decrease of serum PRL, clinical improvement 
and tumour shrinkage. Using light and electron micros- 
copy cellular atrophy, interstitial and perivascular fibro- 
sis were noted; in several tumours connective tissue ac- 
cumulation was pronounced. The cellular response was 
not uniform. In some adenomas populations of large 
cells and small cells were distinguished. The large cells 
contained immunoreactive PRL and expressed the PRL 
gene indicating resistance to dopamine agonists. It ap- 
pears that these cells retained the potential to secrete 
PRL and proliferate despite exposure to dopamine ago- 
nists. In the small cells, PRL immunoreactivity and PRL 
gene expression decreased providing evidence that both 
PRL release and synthesis were blocked. Small cells can 
persist in tumours after discontinuation of dopamine ag- 
onist medication suggesting these small cells are irrever- 
sibly suppressed and are not capable of regaining their 
endocrine function and proliferative capability. The for- 
mation of irreversibly suppressed PRL cells may explain 
why some PRL-producing adenomas do not recur after 
withdrawal of dopamine agonists. 
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Introduction 
A large number of studies have provided conclusive evi- 
dence that dopamine agonist drugs decrease serum pro- 
lactin (PRL) levels, stop amenorrhoea and galactorr- 
boca, restore fertility and libido and cure impotence and 
hypogonadism in patients with PRL-producing pituitary 
adenoma (Barrow et al. 1984; Corenblum 1985; Coren- 
blum and Taylor 1983; Johnston et al. 1983; Jordan and 
Kohler 1987; Molitch 1989; Molitch et al. 1985; Nabar- 
ro 1982; Vance and Thorner 1987). Beside the marked 
clinical and biochemical improvement, substantial tu- 
mour shrinkage has also been documented (Bassetti 
et al. 1984; Chiodini et al. 1981 ; Corenblum and Hanley 
1981 ; Fahlbusch et al. 1987; Hassoun et al. 1985; Lan- 
dolt et al. 1987; McGregor 1979; Nillius etal. 1978; 
Rengachary etal. 1982; Saitoh et al. 1986; Schottke 
et al. 1986; Thorner et al. 1980). In most patients tumour 
involution is reversible, since after discontinuation of 
dopamine agonist medication the tumour regrows, se- 
rum PRL levels rise and the clinical signs and symptoms 
recur (Molitch et al. 1985; Thorner et al. 1981). 
Despite the experience obtained in dopamine agonist 
therapy and the progress in understanding the mecha- 
nism of dopamine agonist action, several questions re- 
main unresolved. It is not clear whether only PRL re- 
lease or both release and synthesis are inhibited in hu- 
man PRL-producing adenomas, nor is it known what 
are the mechanisms and sequence of events in tumour 
involution and regrowth. Further studies are required 
to clarify why some adenomas are resistant to dopamine 
agonist drugs (Bannister and Sheridan 1987; Breidahl 
et al. 1983; Cheyne et al. 1988; Kupersmith et al. 1989; 
Liuzzi etal. 1985; Molitch etal. 1985) whereas other 
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tumours show inreversible shrinkage, serum PRL levels 
fail to increase and the clinical signs and symptoms do 
not return after withdrawal of  dopamine agonist medica- 
tion (Johnston et al. 1984; Moriondo et al. 1985; Wang 
et al. 1987; Zarate et al. 1983). Some of  these questions 
were addressed by previous morphological  investiga- 
tions (Esiri e tal .  1986; Hassoun etal .  1985; Horva th  
and Kovacs 1986; Horva th  et al. 1988; Rengachary et al. 
1982; Saitoh et al. 1986; Tindall et al. 1982); however, 
no definite conclusions were drawn. 
The aim of  the present study was to obtain a deeper 
insight into these problems by studying the tumours  in 
detail using light microscopy, immunocytochemistry  and 
electron microscopy. We correlated the morphology of  
dopamine agonist exposed PRL-producing adenomas 
with P R L  gene expression, applying in situ hybridiza- 
tion. 
Patients and methods 
Twenty-two patients underwent trans-sphenoidal surgery for PRL- 
secreting pituitary adenomas. All patients had marked hyperpro- 
lactinaemia. Six patients received no dopamine agonist therapy. 
Seven patients were treated with one intramuscular injection of 
100 mg bromocriptine (2-bromo-~-ergocryptine, BEC) LAR, a new 
long-acting repeatable injectable form of bromocriptine (Parlodel 
LAR, Sandoz, Basel, Switzerland). This drug was found to be 
effective in the management of patients with PRL-producing ad- 
enoma (Ciccarelli et al. 1987; Grossman et al. 1986; Montini et al. 
1986; Schettini et al. 1988; van't Verlant et al. 1988). Nine patients 
were given bromocriptine (2.5-7.5 mg) daily. In 6 of these patients, 
bromocriptine treatment was discontinued for at least 2 months 
before surgery. The duration of bromocriptine therapy varied from 
3 weeks to 11 months. Serum PRL levels were measured before, 
during and after cessation of bromocriptine administration by ra- 
dioimmunoassay. The clinical signs and symptoms were monitored 
and tumor sizes estimated by various imaging techniques. 
Tumour tissues were fixed in buffered formalin and embedded 
in paraffin. Sections of 4-6 gm were stained with haematoxylin 
and eosin (H&E) and the periodic acid-Schiff (PAS) method. The 
avidin-biotin-peroxidase complex (ABC) technique was used for 
demonstration of hormone content. The following antisera were 
applied: anti-hGH (1:1500 dilution, DAKO, Santa Barbara, Ca- 
lif.), anti-hPRL (1:4000 dilution, provided by Dr. H. Friesen, De- 
partment of Physiology, University of Manitoba, Winnipeg, Mani- 
toba, Canada), anti-hACTH (1:2000 dilution), anti-/3 hTSH 
(1:4000 dilution), anti-/3 hFSH (1:2000 dilution); anti-/3 hLH 
(1:2000 dilution), all donated by NIDDKD (Bethesda, Md.); 
monoclonal anti c~-hSU (1 : 800 dilution, Biogenex, Dublin, Calif.). 
The immunostaining and the control stains were performed as de- 
scribed elsewhere (Asa et al. 1986). 
For electron microscopy small pieces of the tumours were fixed 
in 2.5% glutaraldehyde, postfixed in 1% osmium tetroxide, dehy- 
drated in graded series of ethanol, processed through propylene 
oxide and embedded in Epon-Araldite mixture. Ultrathin sections 
were stained with uranyl acetate and lead citrate and studied with 
a Philips 410-LS electron microscope. 
Using in situ hybridization (ISH) for PRL mRNA and GH 
mRNA demonstration, oligonucleotide probes complementary to 
the region of hPRL 66-72 and hGH 11-17 were exploited. The 
probes were synthesized on an automated DNA synthesizer (Gene 
Assembler) by Pharmacia (Milwaukee, Wis.) using the solid-phase 
beta cyanoethyl phosphor amidite method. The 3-end labelling 
method with 35-S was applied. The sequence of the probes and 
details of the procedures have been described previously (Kovacs 
et al. 1989). 
ISH was performed on 5-gm-thick paraffin sections applying 
5 x 105 cpm of probe as described elsewhere. For combined ISH 
and immunocytochemistry for PRL the ABC method was carried 
out after 2 x standard saline citrate (SSC: 0.15 MNaC1/0.015 M 
trisodium citrate) washings (Kovacs et al. 1989). The following con- 
trols for ISH were performed: (1) predigestion of tissue sections 
with 100 ng/ml RNase A (Sigma, St. Louis, Mo); (2) competition 
studies with 100-fold excess of unlabelled probe to assure specifici- 
ty; (3) human liver and parathyroid adenomas were used as nega- 
tive controls. 
Results 
Biochemical, clinical and imaging findings will not be 
reported here and the effects of  the two different dopa-  
mine agonists will not be compared;  these results will 
be the subject of  a clinical paper  (Fahlbusch et al., in 
preparation).  It suffice to say that  dopamine agonist me- 
dication resulted in reduction of  serum P R L  levels in 
most  cases, clinical improvement  and varying degrees 
of  pituitary adenoma shrinkage. 
By light microscopy, the pituitary tumours  repre- 
sented chromophobic,  slightly acidophilic adenomas.  
The adenomas removed f rom untreated patients had a 
diffuse growth pat tern and were PAS negative. By im- 
munocytochemistry,  the presence of  PRL with the char- 
acteristic disposition in the Golgi area was demonstrated 
in most  adenoma cells. 
In adenomas exposed to bromocr ip t ine-LAR or bro- 
mocriptine up to surgery the most  conspicuous changes 
were the decrease in size of  tumour  cells and the presence 
of  interstitial and perivascular fibrosis. In several tu- 
mours  accumulation of  connective tissue was pro- 
nounced. The degree of  cellular response to dopamine 
agonist varied not only f rom case to case but also, some- 
times, within different areas of  the same tumour  (Ta- 
ble 1). The most  marked morphological  alterations were 
noted in two adenomas (cases 1 and 2) exposed to bro- 
mocript ine-LAR. The small PAS-negative adenoma cells 
possessed scanty cytoplasm around dark, heterochro- 
matic nuclei and were arranged in small groups sur- 
rounded by abundant  connective tissue; deposits of  en- 
docrine amyloid were seen in one of  these adenomas;  
intense perivascular fibrosis was evident as well. PRL 
immunoreactivi ty was absent or weak and restricted to 
few adenoma cells. Three adenomas (cases 5, 8 and 9) 
displayed small cells, but fibrosis was limited to the peri- 
vascular areas and PRL immunoposit ivi ty was present 
in many  cells. In four adenomas (cases 3, 4, 7 and 10) 
areas of  small cells with dark nuclei alternated with 
groups of  cells with euchromatic nuclei and P R L  im- 
munoposit ivity was restricted to the latter populat ion 
of  cells. Two adenomas (cases 6 and 7) were composed 
of  cells with relatively large, lightly stained nuclei, and 
narrow cytoplasm containing evenly distributed P R L  
immunoreactivity. 
Three adenomas removed f rom patients who had 
been off BEC for 2 or more  months before surgery had 
the same morphology as untreated ones; PRL immuno-  
reactivity was intense and present in most  adenoma cells. 
In two adenomas (cases 3 and 4) marked cellular hetero- 
geneity was evident: one adenoma was composed of  
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Table 1. Summary of morphological results in prolactin (PRL)-producing adenomas from ten patients treated with dopamine agonists 
up to surgery 
Case Sex, age BEC dose Duration ICC ISH Ultrastructure 
for PRL for PRL 
1. F, 20 100 mg (LAR) 5 weeks Rare cells Most cells 0; 
rare cells +,  + + 
2. M, 42 100 mg (LAR) 5 weeks Rare cells Most cells 0; 
rare cells +,  + + 
3. F, 48 100 mg (LAR) 15 weeks Few groups Most cells + ; 
of cells few cells + +,  + + + 
4. M, 49 100 mg (LAR) 2 weeks Many cells NA 
5. F, 40 2 x 50 mg (LAR) 3 weeks Most cells Diffuse +,  + + 
6. M, 59 100 mg (LAR) 8 weeks Many cells Diffuse +,  + + 
7. M, 56 100 mg (LAR) 6 weeks Many cells NA 
8. F, 23 2.5 rag/day 1 week Most cells Diffuse +,  + + 
5.0 mg/day 1 week 
7.5 rag/day 6 weeks 
9. F, 27 2.5 mg/day 1 week Most cells Most cells + ; 
5.0 mg/day 2 weeks few + +,  + + + 
7.5 rag/day 3 weeks 
"1 week off 
10. F, 50 10.0 mg/day 4 weeks Most cells, Many cells 0; 




Marked suppression; strong 
fibrosis; amyloid deposits 
Marked or less often moderate 
suppression; moderate fibrosis 
Moderate to marked suppression; 
slight fibrosis 
Moderate to marked suppression; 
perivascular fibrosis; 
few mitoses 
Moderate suppression and 
crinophagy; few cells with 
marked suppression; fibrosis 
Moderate suppression; some 
dead cells; strong fibrosis 
Marked suppression; some dead 
cells; perivascular fibrosis 
Marked suppression; 
perivascular fibrosis 
Moderate to marked suppression; 
perivascular fibrosis 
0, negative labelling; +,  weak labelling; + +,  moderate labelling; + + +,  intense labelling; + + + § very intense labelling; NA not 
available; BEC, 2-bromo-e-ergocryptine; ICC, immunocytochemistry; ISH, in situ hybridization 
Table 2. Summary of morphological results in six PRL-producing adenomas from patients who discontinued dopamine agonist therapy 
before surgery 
Case Sex, BEC dose Duration ICC ISH Ultrastructure 
age for PRL for PRL 
1. F, 17 7.5 mg/day 3 months Most cells Diffuse + +,  + + + Typical 
2 months off 
2. F, 37 5.0 mg/day 6 months Most cells Diffuse + + Typical; some giant 
4 months off mitochondria; mitoses 
3. F, 31 3.7 mg/day 18 months NA NA Few typical; most cells 
2 months off with marked suppression 
4. F, 30 NA NA Most cells NA Typical and suppressed cells 
6 months off 
5. F, 40 7.5 rag/day 4 months Most cells Diffuse + + + 
2 months off 
6. M, 24 5.0 mg/day 11 months Most cells Diffuse + + +,  + + + + 
2 months of 
Typical; 15% of cells 
densely granulated 
Densely granulated cell adenoma 
For legend, see Table 1 
small  cells with dark  nuclei  in te rmingled  with large cells 
con ta in ing  euchromat ic  nuclei ;  however,  the P R L  im- 
m u n o s t a i n i n g  was evenly distr ibuted.  The other  ad- 
e n o m a  exhibited large areas of  small  cells with dark  nu-  
clei and  a m i n o r  p o p u l a t i o n  of  large cells with euchro-  
mat ic  nuclei  (Table 2). P R L  immunopos i t i v i ty  was un-  
even and  per ivascular  fibrosis was marked  in  this tu- 
mour .  
O n  electron microscopy the six t umour s  removed 
f rom un t rea ted  pat ients  showed the characterist ic ul t ra-  
s t ructural  features of  sparsely g ranu la ted  P R L  cell ad- 
enomas  (Horva th  and  Kovacs 1986; Kovacs and  Hor-  
442 
Fig. 1. Sparsely granulated prolactin (PRL) cell adenoma not 
exposed to 2-bromo-e-ergocryptine (BEC) therapy. Note 
euchromatic nucleus with prominent nucleolus. The 
abundant cytoplasm contains well-developed rough 
endoplasmic reticulum (RER) and Golgi complex with 
pleomorphic forming secretory granules; extruded secretory 
granules are seen (arrows). x 9,600 
Fig. 2. Sparsely granulated PRL cell adenoma exposed to 
BEC-LAR up to surgery. The small cells possess indented 
heterochromatic nuclei, small nucleoli and narrow cytoplasm. 
Few RER profiles and scattered small secretory granules, 
some extruded (arrows) are noted. • 9,600 
Fig. 3. Sparsely granulated PRL cell adenoma exposed to 
BEC up to surgery. Large, active cell with well developed 
cytoplasm and euchromatic nucleus is surrounded by small 
cells with heterochromatic nuclei and scarce cytoplasmic 
organelles (asterisks). x 9,600 
vath 1986) (Fig. 1). The adenoma cells possessed euchro- 
matic nuclei with prominent  nucleoli and abundant  cyto- 
plasm. The rough endoplasmic reticulum (RER) was 
well developed, consisting of  parallel cisternae or con- 
centric whorls. Golgi complexes were prominent  and 
contained pleomorphic developing granules. The cyto- 
plasmic secretory granules were usually sparse, electron- 
dense and measured 125-300 nm. The extrusion of  secre- 
tory granulesdnto the intercellular space was a common  
event. ' '~ :L 
Five adenomas (cases 1, 2, 7-9) exposed to dopamine 
agonists up to surgery showed uniform, marked ultra- 
structural signs of  functional suppression (Fig. 2). The 
very small, ovoid, slightly polyhedral adenoma cells con- 
tained smaller, often indented nuclei with coarsely 
clumped heterochromatin and small nucleoli. The nar- 
row rim of  cytoplasm contained scanty R E R  and few 
free ribosomes. In most  adenoma cells, the Golgi com- 
plex was not recognizable. When it was noticeable, it 
was formed by few collapsed sacculi and numerous vesi- 
cles with occasional small forming granules. The majori- 
ty of  secretory granules were very small, measuring 50- 
200 nm, but few of  them reached 300 nm. Misplaced 
exocytoses of  one or multiple secretory granules were 
frequently encountered. 
Three adenomas (cases 3-5) consisted of  sparsely 
granulated cells with ultrastructural signs of  marked, or 
often moderate suppression. The small polyhedral cells 
contained irregular nuclei with discrete or moderate he- 
terochromatinization and nucleoli with variation in size. 
Beside the adenoma cells with small cytoplasm, occa- 
sional adenoma cells with large, well-differentiated cyto- 
plasm and secretory granules measuring up to 450 nm 
were seen (Fig. 3). 
One sparsely granulated PRL cell adenoma (case 6) 
was composed of  small cells with long cytoplasmic pro- 
cesses. The relatively large nuclei contained stippled het- 
erochromatin and moderately developed nucleoli. The 
narrow cytoplasm harbored poorly to moderately devel- 
oped RER and Golgi apparatus. The sparse secretory 
granules were small and many were engaged in exocyto- 
sis. In case 7, the adenoma contained cells with hetero- 
chromatic nuclei but fairly prominent nucleoli. In the 
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narrow cytoplasm a surprisingly abundant  RER, active 
Golgi region and quite numerous small secretory gran- 
ules were present. 
The ultrastructure of  adenomas of patients in whom 
bromocriptine was discontinued showed some variations 
(Table 2). Two adenomas (cases 1 and 2) had the same 
ultrastructure as those not exposed to the drug. Case 5 
was composed of  a predominant  population of  typical 
sparsely granulated PRL cells and a minor component  
(approximately 15%) of densely granulated PRL cells 
with secretory granules measuring up to 900 nm. One 
tumour (case 6) represented densely granulated PRL cell 
adenoma. The abundant spherical secretory granules 
measured 150-600 nm. Many adenoma cells showed ex- 
trusion of secretory granules. The cytoplasmic organelles 
involved in hormone synthesis were well developed as 
in the sparsely granuled variant. Lysosomes and crino- 
phagy were frequently encountered. Two tumours 
(cases 3 and 5) had heterogeneous ultrastructural fea- 
tures with adenoma cells showing considerable variation 
in shape and size. In one adenoma some nuclei were 
Fig. 4. PRL cell adenoma unexposed to BEC. Most cells are immu- 
noreactive for PRL and have an even, intense distribution of PRL 
mRNA. x 400 
Fig. 5. PRL cell adenoma exposed to BEC-LAR up to surgery 
shows marked functional suppression as indicated by the lack of 
both PRL gene expression and gene product, x 400 
Fig. 6. PRL cell adenoma with an uneven reponse to BEC: the 
PRL immunoreactive cells contain abundant PRL mRNA, while 
cells devoid of PRL lack its messenger, as well. x 400 
Fig. 7. PRL cell adenoma in which BEC therapy was discontinued 
2 months before surgery shows the same pattern of PRL immuno- 
reactivity and intensity of PRL mRNA as seen in adenoma unex- 
posed to BEC. x 400 
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euchromatic, while others had coarsely clumped hetero- 
chromatin; there were marked variations in size of the 
cytoplasm and prominence of RER and Golgi com- 
plexes; in many adenoma cells secretory granules were 
sparse and measured up to 300 nm; in some adenoma 
cells the secretory granules were larger and more numer- 
ous than usual. In the other adenoma, most of the ceils 
had hyperchromatic nuclei and small rim of cytoplasm 
with few organelles. 
Using ISH, none of the PRL-producing adenomas 
examined expressed the GH gene. All six untreated PRL 
cell adenomas contained an intense or very intense hy- 
bridization signal for PRL mRNA (Fig. 4). In adenomas 
exposed to dopamine agonists a marked decrease in PRL 
mRNA content was found when compared with the un- 
treated (Table 1). Among PRL cell adenomas with signs 
of marked suppression, the lowest signal level was found 
in two adenomas treated with bromocriptine-LAR. In 
these tumours most adenoma cells were devoid of PRL 
mRNA (Fig. 5). In the other adenomas, including those 
in which moderate morphological response was predom- 
inant, a weak or mild hybridization signal level pre- 
vailed. ISH combined with immunocytochemistry re- 
vealed that in tumours with uneven PRL immunoreac- 
tivity, PRL mRNA was usually abundant in PRL im- 
munopositive cells and scanty or absent in the adenoma 
cells which failed to stain for PRL (Fig. 6). 
In adenomas in which bromocriptine therapy was dis- 
continued a few months before surgery, the intensity 
of labelling for PRL mRNA was comparable with that 
of untreated adenomas (Table 2) (Fig. 7). A high level 
of mRNA was found in both sparsely and densely granu- 
lated adenoma cells. In the two tumours with different 
degrees of suppression, ISH revealed adenoma cells with 
variable intensity of labelling for PRL mRNA and ad- 
enoma cells lacking the messenger. 
Discussion 
The present investigation confirms and extends previous 
findings and provides conclusive evidence that treatment 
with dopamine agonists causes profound morphological 
alterations in PRL-producing pituitary adenomas (Has- 
soun et al. 1985; Horvath and Kovacs 1986; Horvath 
et al. 1988; Saitoh et al. 1986; Schottke et al. 1986; Tin- 
dall et al. 1982). In earlier studies (Tindall et al. 1982) 
dopamine agonist medication was found to induce 
marked cellular involution manifested by reduction of 
cellular, cytoplasmic, nuclear and nucleolar sizes, in- 
crease of nuclear-cytoplasmic ratio and decrease of cyto- 
plasmic volume densities of endoplasmic reticulum and 
Golgi complexes. Compared to PRL producing ad- 
enomas removed from patients not exposed to dopamine 
agonists, the cytoplasmic volume densities of mitochon- 
dria and in many cases, those of the lysosomes exhibited 
no major change and the cytoplasmic volume densities 
and diameters of secretory granules showed slight in- 
crease in some adenomas and no change or slight de- 
crease in others. In a few tumours accumulation of lyso- 
somes was noted especially in those in which cellular 
shrinkage was not marked. Although no morphometry 
was applied in the present study, the cellular involution 
was obvious. The clinical and biochemical results were 
concordant with the morphological alterations and were 
manifested by decrease of serum PRL levels as well as 
restoration of menstruation, cure of galactorrhoea, hy- 
pogonadism and impotence and improvement of libido. 
Tumour shrinkage was documented before surgery by 
various imaging techniques. 
Apart from the morphological changes affecting the 
adenoma cells varying degrees of interstitial and perivas- 
cular fibrosis was noted by previous workers (Esiri et at. 
1986; Landolt and Osterwalder 1984) and in the present 
study. A marked individual difference was evident 
among various tumours. Accumulation of connective tis- 
sue was more pronounced in the tumours of patients 
who had protracted dopamine agonist medication with 
relatively large doses and in whom tumour shrinkage 
was extensive. The factors accounting for the develop- 
ment of fibrosis are not known. No widespread cellular 
death was evident; thus it is unlikely that extensive ne- 
crosis preceded and was responsible for the accumula- 
tion of connective tissue. It may be that mediators were 
released from the shrinking tumour cells which evoke 
proliferation of connective tissue. This interpretation is, 
however, speculative and is not supported by any evi- 
dence so far. 
Similar to the clinical and biochemical results the 
morphological changes were found to be reversible in 
many tumonrs. In some tumours following withdrawal 
of dopamine agonist medication the structural features 
were indistinguishable from those removed from patients 
not receiving dopamine agonist drugs. In these tumours 
the adenoma cells were large, possessing abundant cyto- 
plasm, conspicuous endoplasmic reticulum network, 
many free ribosomes and polysomes and prominent Gol- 
gi complexes. 
Hybridization histochemistry using an oligonucleo- 
tide probe demonstrated a marked decrease of PRL 
mRNA in many tumours indicating that not only PRL 
release but also PRL synthesis was suppressed by dopa- 
mine agonist medication. These results, using ISH meth- 
odology, are in agreement with previous findings ob- 
tained in animal pituitaries which showed a significant 
reduction of PRL gene expression secondary to dopa- 
mine agonist exposure (Maurer 1980). 
A marked individual variation in the cellular response 
to dopamine agonist medication was a striking finding 
in the present study. In some tumours removed from 
patients treated with dopamine agonists two different 
cell populations were clearly identified; one seemed to 
have escaped dopamine agonist suppression. These ad- 
enoma cells were large, their PRL content was not de- 
creased and PRL gene expression appeared to be within 
the normal range. The other cell population consisted 
of small cells exhibiting the effect of dopamine agonist 
suppression characterized by marked cellular involution, 
decrease of immunoreactive PRL content and PRL 
mRNA. 
The finding that differences exist in cellular respon- 
siveness to dopamine agonists is difficult to explain. It 
may be that functional dopamine receptors (Bression 
445 
et al. 1980; Bronin  1982; K o g a  et al. 1987) are missing 
on the surface o f  some a de nom a t ous  P R L  cells or  im- 
pa i rment  o f  some intracellular event accounts  for  the 
resistance to dopamine  agonists.  The degree o f  clinical 
and  biochemical  resistance depends on the number  o f  
unresponsive large cells which are capable o f  expressing 
the P R L  gene and its p roduc t  and  presumably  have a 
potent ial  for  g rowth  despite exposure to dopamine  ago-  
nists. I f  unresponsive large cells p redomina te  in a tu- 
rnout  exposed to dopamine  agonist  medicat ion,  little 
suppressive effect can be expected f rom the drug. 
It has been noted  by several authors  tha t  some pa-  
tients are resistant to dopamine  agonist  therapy (Bannis- 
ter and  Sheridan 1987; Breidahl e ta l .  1983; Cheyne 
e ta l .  1988; Kupersmi th  e ta l .  1989; Liuzzi e ta l .  1985; 
Moli tch et al. 1985). In other  patients t u m o u r  involut ion 
is permanent ,  t u m o u r  regrowth  fails to occur  and hyper-  
pro lac t inaemia  as well as the clinical symptoms  do no t  
revert  after d iscont inuat ion  o f  dopamine  agonist  medi-  
ca t ion ( Johns ton  e ta l .  1984; M o r i o n d o  e ta l .  1985; 
Wang  et al. 1987; Zara te  et al. 1983). It appears  that  
such tumours  are composed  o f  markedly  suppressed 
small P R L  cells tha t  are no t  able to secrete P R L  in 
excess and  do no t  cont inue to proliferate. It  is conceiv- 
able tha t  those small cells which conta in  no immunore -  
active P R L  and do no t  express the P R L  gene even after 
d iscont inuat ion  o f  dopamine  agonist  therapy lose the 
potent ial  to regain endocr ine  activity and  growth,  in 
some cases irreversibly. The development  o f  a clone o f  
irreversibly suppressed P R L  cells m a y  provide  an expla- 
na t ion  o f  why  some adenomas  do no t  cause hyperprolac-  
t inaemia and do no t  regrow after wi thdrawal  o f  dopa-  
mine agonist  medicat ions.  
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